研究表明,鼻喷雾中使用的阿泽拉斯可以在健康的成年人中降低67%的COVID-19风险. Study suggests nasal spray azelastine may reduce COVID-19 risk by 67% in healthy adults.

最近发表在"美国医学杂志" (JAMA Internal Medicine) 上的一项研究表明,用于季节性过敏的非处方鼻喷剂azelastine可能会显著降低COVID-19感染的风险. A recent study published in JAMA Internal Medicine suggests that an over-the-counter nasal spray, azelastine, used for seasonal allergies, may significantly reduce the risk of COVID-19 infections. 德国研究人员对450名健康成年人进行的试验显示,每天使用喷雾剂3次的人中的感染人数减少了67%。 The trial, conducted by German researchers on 450 healthy adults, showed a 67% reduction in infections among those using the spray three times daily. 虽然研究显示喷雾组的呼吸道感染减少,但由于样本规模小和其他限制,还需要进一步研究。 While the study indicates fewer respiratory infections in the spray group, further research is needed due to the small sample size and other limitations.